Caglar, Hasan OnurAytatli, AbdulmelikBarlak, NeslisahKaratas, Elanur AydinTatar, ArzuSahin, AbdulkadirKaratas, Omer Faruk2026-03-262026-03-2620241043-30741097-034710.1002/hed.278032-s2.0-85193526806https://doi.org/10.1002/hed.27803https://hdl.handle.net/20.500.14901/3209Çağlar, Hasan Onur/0000-0002-3637-4755;Background: This study aimed to identify a candidate gene associated with paclitaxel (PTX) resistance and to evaluate functionally its biological role in the PTX-resistant head and neck squamous cell carcinoma (HNSCC) cell lines and clinical specimens. Methods: Microarray data series containing samples of different types of cancers resistant to PTX were analyzed and then a candidate gene associated with PTX resistance was identified using various bioinformatics tools. After the suppression of the target gene expression, changes in cell viability and colony-forming ability were evaluated in PTX-resistant FaDu and SCC-9 cell lines. Results: Bioinformatics analyses of upregulated genes in PTX-resistant cancer cells indicated that OAS3 was associated with PTX resistance. The downregulation of OAS3 expression significantly reduced the viability and colony-forming capacity of PTX-resistant SCC-9 cells by inducing apoptosis and cell cycle arrest at G0/G1 phase. Conclusions: The therapeutic targeting of OAS3 may resensitize PTX-resistant HNSCC cells with high OAS3 expression to PTX treatment.eninfo:eu-repo/semantics/openAccessFaduHead and Neck Squamous Cell CarcinomaOAS3Paclitaxel ResistanceSCC-9Article